Norovirus Diagnostics Market

Market Study on Norovirus Diagnostics: Over Half Market Share Held by Diagnostic Laboratories

Norovirus Infection Diagnostics Market Segmented By Rapid Test Kits, PCR Kits, ELISA-based kits Product

  • October-2021
  • PMRREP25924
  • 245 Pages
  • Healthcare

Market Snapshot

Global demand for norovirus diagnostics has an estimated market value of around US$ 50.6 Mn as of 2021, and the norovirus diagnostics market across the world is projected to experience significant expansion at 8.4% CAGR from 2021 to 2031. As per Persistence Market Research’s projections, rapid test kits held substantial share of over 56% in 2020 in the global norovirus diagnostics market.

Data Points

Market Insights

Market Value 2021

US$ 50.6 Mn

Market Value 2031

US$ 114 Mn

CAGR 2021-2031


Key Market Players

  • Abbott
  • R-Biopharm AG
  • ELITechGroup AG
  • Danaher Corporation (Cepheid)
  • Luminex Corporation

Collective Value Share: Top 3 Countries (2021E)


Find Out More about the Report Coverage


  • Abbott
  • R-Biopharm AG
  • Cepheid
  • Luminex Corporation
  • Meridian Bioscience
  • ELITechGroup
  • Biomérieux SA
  • CerTest Biotec S.L.
  • Elisabeth Pharmacon, Spol. S Ro
  • Qiagen
  • Altona Diagnostics GmbH
  • Eiken Chemical Co.

Sales Analysis of Norovirus Diagnostic Products from 2016 to 2020 Vs Market Outlook for 2021 to 2031

The global norovirus diagnostics market expanded at 4.2% CAGR over the past 5 years.

There has been an increase in the use of various norovirus diagnostic products such as PCR and rapid tests as measures for the diagnosis of norovirus infections. This is due to the better performance of these products for the detection of norovirus. This has subsequently resulted in higher demand for rapid tests for the detection of norovirus.

The global market is expected to expand at a considerable growth rate over the next ten years at a CAGR of around 8.4% and reach a valuation of US$ 114 Mn.

Customize this Report

Explore Intelligence Tailored to Your Business Goals.

What are the Key Opportunities for Norovirus Diagnostic Product Manufacturers?

The global market is characterized by high levels of opportunistic focus as a result of elaborate strategies employed by prominent players and manufacturers. Rising prevalence of the norovirus illness has prompted medical device companies to invest in research & development.

The norovirus infection diagnostics market is likely to rise in the near future as key companies increase their efforts in new and advanced product development that is more sensitive and quick. Furthermore, in developing countries, increasing approval and commercialization of norovirus diagnostics are creating enormous prospects for market players.

Rise of diagnostics labs also illustrates the impact on the market. The benefits of expanding emergence of diagnostics labs include a positive impact on manufacturers' sales and revenue. The Indian diagnostics industry consists of 47% of standalone diagnostics centres and 16% of diagnostics chains.

Furthermore, there is rise in the prevalence of norovirus. According to CDC, norovirus is the most frequent cause of acute gastroenteritis, generating an estimated 685 million cases per year. Around 200 million instances are detected among children under the age of five, resulting in an estimated 50,000 child fatalities per year, primarily in poorer nations.


Market Research Methodology - Perfected through Years of Diligence

A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.

Get actionable insights on Ship Repair And Maintenance Services Market

What are the Main Factors Restraining Demand for Norovirus Diagnostics?

There is prevailing social as well as economic factors restraining market growth. Burden of the prevalence of norovirus infection in countries with developing economies and lack of awareness about the symptoms leading to norovirus infection adversely affect market growth.

Furthermore, the internalized stigma of not consulting physicians for norovirus infection due to lack of awareness has led to under-diagnosis of norovirus, and thus poses a burden on patient health and wellbeing. Symptoms caused by norovirus include nausea, vomiting, diarrhoea, cramping, and low-grade fever. These symptoms are commonly caused by many other infections as well. Hence, there are high chances that the disease may be misdiagnosed. Moreover, these mild symptoms are generally ignored by people.

Furthermore, presence of a large number of potential competitors in the market has resulted in pricing competition among manufacturers, which has acted as a limiting factor to the adoption of norovirus diagnostic products.

Explore Persistence Market Research’s expertise in promulgation of the business !

Country-wise Insights

Why is the U.S. a Leading Market for Norovirus Diagnostics?

The U.S. dominates the North American region with a market share of

80% in 2021, and is forecasted to progress rapidly throughout the next ten years.

Prevalence of norovirus infection, presence of major players, and increased research & development spending are resulting in the high share of the country in the region. In addition, rise in initiatives undertaken by the government and authorities to develop healthcare systems is projected to drive market growth.

The U.S. government has taken initiatives for improving research and regulatory capacity. For instance, according to the U.S. FDA premarket approval database, the approval rate increased by 25% in 2020.

Will Germany Be a Lucrative Market for Norovirus Diagnostics in Europe?

Germany dominates the European market for norovirus diagnostics with a share of 23.4%.

Growth of this market is mainly driven by the presence of major players and collaborations done by them for the development of new products. People's willingness and ability to spend on wellness has resulted in a significant shift in healthcare spending.

  • For instance, in December 2020, Altona Diagnostics GmbH launched AltoStar Norovirus RT-PCR Kit 1.5, an automated in-vitro diagnostic test for the detection of norovirus genogroup I (GI) and II (GII).
  • In March 2018, R-Biopharm AG collaborated with Bosch Healthcare Solutions for the development of an all-in-one platform for molecular diagnosis.

How is India an Emerging Market for Norovirus Diagnostics?

Over the decade, the market in India is projected to surge at a CAGR of 13.3%.

Investments in R&D and technology, especially in life sciences, have shifted from North America and Europe to Asia Pacific. Another factor driving the market is collaborations between companies and government authorities.

What is the Outlook for China Regarding Norovirus Diagnostics?

In 2020, Japan dominated the East Asia market with 50%. However, over the forecasted period, the market in China is expected to grow exponentially at a CAGR of 14%.

Manufacturers are focusing on expanding their global presence and increasing their specialized expertise with exclusive technological capabilities, leading to better availability of norovirus diagnostic products in China.

Category-wise Insights

Which Norovirus Diagnostic Product is Driving Market Growth?

By product, rapid test kits project high growth potential at a CAGR of 9.8% through 2031.

A technique such as ELISA is not sensitive enough for the detection of norovirus and not useful in real-time diagnosis. To overcome this, currently, polymerase chain reaction (PCR) is extensively used for detection. Companies are coming up with techniques that are rapid and more sensitive, which will provide results in less than one hour, as such, driving the growth of this segment.

Which End User is Dominating Demand for Norovirus Diagnostic Products?

Based on end user, diagnostics laboratories lead the way with more than 50% market share. Development of standalone diagnostic laboratories and diagnostics chains are driving segment growth.

Impact of COVID-19

The norovirus diagnostics industry suffered a negative impact during the COVID-19 pandemic. Major reason that can be attributed to this is the halt in manufacturing due to COVID-19-related lockdowns worldwide. Due to this, the supply chain of medical devices was adversely affected.

Apart from this, there was negligence in attending to infections such as norovirus. Everyone was more focused on preventing COVID-19 and its adverse effects.

What is the Impact of Market Consolidation on the Norovirus Diagnostics Business Space?

Considering consolation activities in the global market, mergers and acquisitions have emerged as one of the key growth strategies by market players. Prominent players are strengthening their product ranges through acquisitions and reaching out to key as well as emerging markets.

  • In August 2016, Danaher Corporation completed the acquisition of Cepheid, a molecular diagnostics company, thus essentially accommodating a joint venture for expansion of its product portfolio for diagnostics.

Competitive Landscape

Key players are focusing on expansion in emerging regions and new revised product manufacturing. The strategy of expansion, new product launches, and approvals by key manufacturers are further strengthening their market presence.

  • In February 2017, Meridian Bioscience Inc. launched TruQuick rapid tests for the Asia Pacific region. This helped the company expand in the Asia pacific region and other emerging markets across the globe.
  • In April 2018, R-Biopharm AG received FDA approval for RIDA-GENE Norovirus GI/GII for the detection and differentiation of norovirus genogroup I (GI) and II (GII).

Similarly, recent developments related to companies manufacturing norovirus diagnostic products have been tracked by the team at Persistence Market Research, which are available in the full report.

Norovirus Diagnostics Market Report Scope



Forecast Period


Historical Data Available for


Market Analysis

  • US$ Mn for Value
  • Volume (in units)

Key Regions Covered

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Middle East & Africa

Key Countries Covered

  • US
  • Canada
  • Brazil
  • Mexico
  • Argentina
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Benelux
  • Russia
  • China
  • Japan
  • South Korea
  • India
  • Thailand
  • Indonesia
  • Malaysia
  • Thailand
  • Indonesia
  • Australia and New Zealand
  • Egypt
  • Turkey
  • South Africa
  • North Africa
  • GCC Countries

Key Market Segments Covered

  • Product
  • End User
  • Region


Available upon Request

Key Segments Covered in Norovirus Diagnostics Industry Research

By Product

  • Rapid Test Kits
  • PCR Kits
  • ELISA-based kits

By End-User

  • Hospitals
  • Diagnostics Labs
  • Clinics

- FAQs -

The global norovirus diagnostics market was worth US$ 47.6 Mn in 2020, and is set to expand 2.2X over the next ten years.

The global market is expected to reach US$ 114 Mn by the end of 2031, with sales revenue expected to register 8.4% CAGR.

From 2016-2020, the market for norovirus diagnostics expanded at the rate of 4.2%, mainly on the back of rise in norovirus infections worldwide.

Increasing government initiatives, development of rapid tests for the detection of norovirus infection, and key players acquiring other companies or brands are some of the key trends being witnessed in this marketplace.

The U.S., Germany, Canada, U.K., and Japan are expected to drive most demand for norovirus diagnostic products.

North America is one of the key markets for norovirus diagnostics, with the U.S. expected to account for over 80% of this regional market.

Demand for norovirus diagnostic products in Europe is expected to register growth of 7.4% CAGR over the next ten years.

The U.S., Germany, Canada, U.K., and Japan are key producers of norovirus diagnostic products.

The South Korean market appears to uphold the least share in the region of East Asia, but is expected to exhibit lucrative growth at a CAGR of 7.8%. Japan holds a revenue share of 50% in this regional market.


Primary Hepatocytes Market

The global primary hepatocytes market was valued at US$ 213.8 Mn in 2021, with an estimated CAGR of 6.6% for the next ten years, which suggests highly progressive market growth..

Prepackaged Medical Kits Trays Market

The global market for pre-packaged medical kits and trays is anticipated to showcase a stellar CAGR of 8.3% during the forecast period, reaching a market value of over US$ 29,000 Mn by the end of 2026..

Infection Surveillance Solutions Market

Global infection surveillance solution market to increase from more than US$ 300 Mn in 2017 to about US$ 905 Mn by 2025 end, representing a CAGR of 14.04% from 2017-2025.

Hospital Acquired Infection Control Market

Global Hospital Acquired Infection Control market is expected to be valued US$ 55 Bn & expand at a CAGR of 3% during forecast period of 2021-2026.

Our Clients

Our Clients